investorscraft@gmail.com

Intrinsic ValueYomeishu Seizo Co., Ltd. (2540.T)

Previous Close¥4,270.00
Intrinsic Value
Upside potential
Previous Close
¥4,270.00

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2025 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Yomeishu Seizo Co., Ltd. operates in the beverages and quasi-pharmaceutical sectors, specializing in herbal liqueurs, craft gin, and health-focused products. Its core revenue model hinges on domestic and international sales of its signature Yomeishu herbal liqueur, alongside complementary offerings like medicinal drinks and quasi-pharmaceuticals. The company diversifies its income streams through real estate leasing, restaurant management, and renewable energy sales, leveraging its heritage brand to sustain niche market appeal. Positioned in Japan’s competitive distillery industry, Yomeishu maintains a unique foothold by blending traditional herbal remedies with modern consumer preferences, targeting health-conscious and premium beverage buyers. Its direct-to-consumer e-commerce platform further strengthens its market presence, while regional expansion in Asia supports incremental growth. The company’s multi-pronged approach mitigates sector volatility, though its reliance on domestic demand and limited global penetration presents both stability and scalability challenges.

Revenue Profitability And Efficiency

Yomeishu reported revenue of ¥10.24 billion for FY2024, with net income of ¥952.8 million, reflecting a net margin of approximately 9.3%. Operating cash flow stood at ¥667.5 million, though capital expenditures of ¥2.49 billion indicate reinvestment in operations. The absence of debt and a cash reserve of ¥7.65 billion underscore prudent financial management, supporting liquidity and flexibility.

Earnings Power And Capital Efficiency

The company’s diluted EPS of ¥68.9 demonstrates steady earnings power, supported by its diversified product mix and asset-light quasi-pharmaceutical segment. Capital efficiency is tempered by significant capex, likely tied to real estate or energy projects, but zero debt and high cash reserves suggest conservative leverage and robust interest coverage.

Balance Sheet And Financial Health

Yomeishu’s balance sheet is notably strong, with no debt and ¥7.65 billion in cash equivalents. This positions the company to weather economic downturns or invest opportunistically. The lack of leverage and substantial liquidity metrics indicate low financial risk, though the high capex may pressure short-term cash flows.

Growth Trends And Dividend Policy

Growth appears modest, with revenue concentrated in Japan, but regional exports and energy ventures offer potential upside. The dividend payout of ¥45 per share aligns with a shareholder-friendly policy, though yield sustainability depends on maintaining profitability amid capex demands. Historical stability suggests cautious but reliable returns.

Valuation And Market Expectations

With a market cap of ¥42.3 billion and a beta of 0.013, Yomeishu trades as a low-volatility defensive stock. Its valuation likely reflects steady cash flows and niche market positioning, though limited growth prospects may cap multiples. Investors likely prize its resilience over aggressive expansion.

Strategic Advantages And Outlook

Yomeishu’s strategic advantages include brand heritage, diversified revenue streams, and a debt-free balance sheet. Near-term outlook hinges on domestic demand stability and energy/real estate ventures, while long-term growth may require deeper Asian market penetration or product innovation. The company’s conservative approach ensures stability but may limit upside.

Sources

Company disclosure, market data

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2026202720282029203020312032203320342035203620372038203920402041204220432044204520462047204820492050

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount